Clinical Trials
90 trialsAntibiotic Prophylaxis in Percutaneous Nephrostomy Placements and Replacements for Malignant Urinary Tract Obstruction
Barretos Cancer Hospital
CISTO
University of Washington
AVENANCE
Pfizer
A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer
Pfizer
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Pfizer
A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Pfizer
Description of Relugolix Use in Patients With Prostate Cancer Within the VHA
Pfizer
A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After Chemotherapy
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
An Observational Study to Evaluate the Efficacy and Safety of Avelumab + Axitinib Combination in Participants With aRCC (AVION)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
REASSURE
Bayer
TEP-Vessie
Institut Bergonié
RAVI Registry
Terumo Medical Corporation
Post-Marketing Surveillance Study To Observe INLYTA® Treatment Dosing Pattern, Safety And Effectiveness In Taiwan Real World Routine Practice
Pfizer
PRIORITY
Institut Bergonié
IP3-PROSPECT
Imperial College London
A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces
Pfizer
An Observational Study of Radiotherapy After Injection of SpaceOAR Hydrogel
Boston Scientific Corporation
PC-CONCEPT
Weill Medical College of Cornell University
Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma
Takeda
SOGUGCOVID
Spanish Oncology Genito-Urinary Group
A Study to Learn About the Study Medicine (Avelumab) in Japanese Patients With Urothelial Carcinoma That Has Spread
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
J-DART2
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma (aRCC) Receiving Systemic First-line (1st Line) Anti-cancer Treatment Under Daily Routine in Germany: Retrospective Medical Chart Review (RENALISTIC Study).
Pfizer
To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma
Pfizer
A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.
Pfizer
FIRMAGON® Intensive Drug Monitoring
Ferring Pharmaceuticals
Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)
Pfizer
Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
Pfizer
Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC
Pfizer
A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine.
Pfizer
Treatment Patterns With Targeted Therapies In Mrcc In Sweden - A Retrospective Analysis Of Data From National Registries
Pfizer
OPTIMISE
Pfizer
TRACE
Boston Scientific Corporation
Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease
Vanderbilt University Medical Center
PET Imaging in MCI Following ADT for PCa
Imperial College London
Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART)
Pfizer
Neutrophil-to-Lymphocyte Ratio in Bladder Cancer: A Secondary Biomarker Analysis of SWOG 8710
Abramson Cancer Center at Penn Medicine
Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan)
Pfizer
Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments
Pfizer
Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib
Pfizer
Evaluating the Shared Decision Making Process Scale in Cancer Screening Decisions
Massachusetts General Hospital
Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan
Pfizer
Online Trial Examining Validity and Reliability of the Shared Decision Making Process Survey
Massachusetts General Hospital
A Retrospective Medical Record Review of First-Line Sunitinib Administration Schedules and Outcomes Among Patients With mRCC in Latin America (LA)
Pfizer
"Retrospective Study to Identify Clinical Factors Related to a High Benefit of Axitinib in mRCC"
Pfizer
PHRC2003
Institut Bergonié
PROSTAGRAM
Imperial College London
ATILA
Pfizer
TROYA
Pfizer
Optimizing the Effectiveness of Routine Post-treatment Surveillance in Prostate Cancer Survivors
Alliance Foundation Trials, LLC.